Category: Cancer

Dr. David Samadi:Is A Well Known Physician

*An in depth look at Dr. David Samadi:

Dr. David Samadi is a well known Physician and the head of the Urology Department at Lennox Hill Hospital. Lennox Hill Hospital is located within the heart of Manhattan. Dr. Samadi has built an excellent reputation for himself since he began practicing Urology well over two decades ago.

Dr. Samadi is Board Certified and he specializes in the diagnosing and treatment of Prostate Cancer, Bladder Cancer as well as diseases which affect the Kidneys. Dr. Samadi employs minimally invasive surgical procedures which reduce time in surgery as well as potential risks associated with surgery. In addition, minimally invasive surgery will cause less scarring and possibility of infection is significantly reduced.

Dr. Samadi uses the method of Laparoscopic Robotic Radical Prostatectomy on a regular basis. This method is successful when performing minimally invasive procedures for Prostate as well as Bladder Cancer procedures.

David Samadi graduated from Stoney Brook University with a degree in Biochemistry. In addition, he attended the Stoney Brook School of Medicine where he received his medical degree. Dr. Samadi was fortunate enough to receive a full paid Scholarship at Stoney Brook School of Medicine. Dr. Samadi took his studies seriously and he graduated medical school with top honors.

Earlier in his career, Dr. Samadi practiced at Columbia Presbyterian Hospital. After six years of Head of Urology, Dr. Samadi decided to leave Columbia Presbyterian and begin practicing at Lennox Hill Hospital. Actually, it was learned that Lennox Hill Hospital approached Dr. Samadi about a position within their Urology department. However, Dr. Samadi initially declined but decided to make the move after he reached his six year mark at Columbia Presbyterian.

Dr. Samadi is considered a celebrity Physician. He has appeared on numerous Television programs such as Fox & Friends and Good Morning America. Normally, Dr. Samadi discusses latest techniques and technologies associated with Bladder and Cancer surgeries. Dr. Samadi has been discussed frequently on CNBC as well as the Bloomberg Network.

Three years ago, Dr. Samadi appeared on a special segment of Fox & Friends to discuss the inflated insurance premiums that some women are forced to pay. Dr. Samadi feels that in most cases insurance companies do not have justification for charging such outrageous premiums especially for females.

Dr. Samadi stresses the importance of preventative testing for the screening of certain common Cancers. In addition, he agrees that insurance companies need to be examined more closely when it comes to patients being forced to pay higher premiums. For more info about us: click here.

Dr. Samadi is currently a member of the American Urological Association. In addition, Dr. Samadi is also a member of the American Medical Association. Dr. Samadi currently holds a valid license to practice medicine and surgery within the state of New York.

Dr. Mikhail Blagosklonny and His Vigilant Fight Against Ageing

Dr. Blagosklonny has been interested in the world of medicine from a very young age, explaining why he acquired both his M.D. in Internal Medicine and Ph.D. in experimental medicine and cardiology from the First Pavlov State Medical University Of St. Petersburg. His performance was so exemplary to the point that he qualified for a job at New York Medical College in Valhalla as an associate professor in 2002.Once he was done with that, Dr. Blagosklonny went on to challenge himself with a position in Ordway Research Institute as a Senior Scientist right before ending up at Roswell Park Cancer Institute as an Oncology Professor in 2009. That was when his research in rapamycin intensified and made enormous progress.Dr. Blagosklonny has been in the business of making sure that he finds much better and less invasive ways of treating cancer. He ensured that he was always in a position to get work done by developing an anti aging drug called rapamycin, one that he later wrote a paper on about how it can be utilized properly.

Dr. Blagosklonny wrote that the use of rapamycin would go a long way in slowing the aging rate as it targets particular cells that trigger the latter hence making the entire process slower. In layman terms, the medication has some rather straightforward modus operandi which acts on the principle of protecting healthy cells from damage as the cancer cells are attacked.The use of rapamycin, Dr. Blagosklonny stated, will most likely affect the TOR signaling in aging and cancer, which can without a doubt boost the lifespan of the consumer. He attributed old age to cells being damaged, and since our bodies to rejuvenate them as fast as possible, they die off at a much faster rate than normal which is the cause of aging.When healthy cells are protected, then the body functions will always work which will result in a boost in the immune system. And since he had spent a couple of years studying bio gerontology (which is the science of studying the underlying body mechanisms that result to aging).

Dr. Blagosklonny has been able to consider the kind of effects that patients who consume rapamycin are having, both in the short and long term.Apart from being an adroit researcher and scientist, Dr. Blagosklonny is also known for his impressive writing as reflected in quite some publications that sparked a worldwide interest once published. Some of his publications include Cancer Biology & Therapy where he was both a contributor and editor.In total, the brilliant oncology specialist has written close to 270 pages in total, making sure that he shares his knowledge with millions of people around the globe. The latter has resulted to his effective outsourcing over 25,000 citations over the years.Others include Aging, where he was the editor in chief as well as Oncotarget. He also was the editor in chief in Cell Cycle after he carried out an in-depth research on the subject matter. In all the above publications, all of which Dr. Blagosklonny (@Mikhail Blagosklonny) is responsible for making happen, he always made sure that he recommends the use of rapamycin.

How Eric Lefkofsky’s Company is Changing the War on Cancer

Four in 10 Americans are expected to develop cancer at some point in their lives. Fortunately, much progress has been made in the diagnosis and treatment of this dreaded disease, and many of the advances in this area are attributable to the work done by such companies as Tempus. This Chicago-based firm has developed a method that can improve cancer treatment through the principle of human genome sequencing.

Although many types of cancer treatment are available today, the effectiveness of any one method often comes down to understanding the specific needs of the person receiving treatment. Tempus has satisfied these needs by developing a platform that can analyze the clinical and molecular composition of individual patients. The result is a major transformation in the way medical health care delivered.

Eric Lefkofsky, who helped establish Tempus, faced a personal crisis when his wife Liz was diagnosed with breast cancer. It was then that he also learned of the inadequacies in the manner that cancer data was being collected and stored. This problem was overcome by the software that would be developed by his company. Possessing language and character recognition capabilities, this software enabled the faster processing of patient information that is often recorded by hand. Notes could thus be transformed into structured data that could be used in the treatment process.

The work by Tempus will help shift treatment strategies to techniques targeting molecules and cells. The end result will be the development of specific treatments that can be more effective and less costly. Such personalized methods may eventually extend from cancer to the treatment of other diseases.

Although he has been long associated with Chicago, Eric Lefkofsky was born in Detroit. A graduate of the University of Michigan Law School, he would later teach at Kellstadt Graduate School of Business, a division of DePaul University, and at the Kellogg School of Business, which is part of Northwestern University. He is currently adjunct professor at the Booth School of Business division of the University of Chicago.

In addition to his academic service, the 47-year-old entrepreneur serves on the boards of some notable organizations, including the Ann and Robert H. Lurie Children’s Memorial Hospital and the Art Institute of Chicago.

About Eric Lefkofsky: